

UROPLASTY INC
Form 425
December 22, 2014

Filed by Uroplasty, Inc.
pursuant to Rule 425
Under the Securities Act of 1933
Deemed filed pursuant to Rule 14a-12
Under the Securities Exchange Act of 1934

Subject Company: Uroplasty, Inc.
Commission File No. 001-32632

Good Morning!

We are excited to bring you the news that Uroplasty and Vision-Sciences have agreed to combine into a new medical device company, Cogentix Medical. The joint news release we issued this morning describes the transaction in detail and is attached. The new company is expected to generate revenue of approximately \$50 million for the fiscal year beginning April 1, 2015 as our combined global sales force will be offering the minimally-invasive Urgent PC and Macroplastique product lines, as well as the Vision-Sciences' proprietary EndoSheath® Endoscopy platforms once we complete the transaction, which is expected in the first half of 2015.

Cogentix Medical will trade on the NASDAQ under the symbol CGNT. The combined company will be headquartered at the current Uroplasty offices in Minnetonka, MN, while maintaining operations for the Vision-Sciences products in Orangeburg, NY and Natick, MA. Rob Kill will become President & CEO of Cogentix Medical, joined by Brett Reynolds as Chief Financial Officer and Darin Hammers as Senior Vice President of Global Sales and Marketing.

We are very excited about the potential for this new company. Cogentix Medical will be able to offer greater value through the Urgent PC and Macroplastique products along with the EndoSheath Endoscopy technology. More than five million units of the sterile disposable EndoSheath technology have been sold with ZERO cases of cross contamination and associated hospital acquired infections. Once we complete the transaction, our goal is to turn the platform's efficacy leadership into market leadership, making the EndoSheath technology the standard of care, while continue to build on the growth that Urgent PC has in treating the symptoms of overactive bladder.

The Board of Directors and management teams of both companies see Cogentix Medical as a platform for continuing growth in the urology market while enabling expansion within other markets outside of urology, namely ENT and pulmonology, through future additions to our portfolio.

We appreciate the value that you, as a supply partner, provide in recognizing our future goals and we will keep you informed of our progress. We expect our combination to be complete in the first half of 2015, and we look forward to working with you through this process as we evolve into Cogentix Medical.

Uroplasty, Vision-Sciences, their respective directors, executive officers and employees may be deemed to be participants in the solicitation of proxies from Uroplasty's and Vision-Sciences' respective shareholders in connection with the proposed transaction. Information about the directors and executive officers of Uroplasty and their ownership of Uroplasty stock is set forth in Uroplasty's annual report on Form 10-K for the fiscal year ended March 31, 2014, and its proxy statement for its 2014 annual meeting of shareholders, which was filed with the SEC on July 22, 2014. Information regarding Vision-Sciences' directors and executive officers is contained in Vision-Sciences' annual report on Form 10-K for the fiscal year ended March 31, 2014 and its proxy statement for its 2014 annual meeting of shareholders, which was filed with the SEC on June 17, 2014. These documents can be obtained free of charge from the sources indicated above. Certain directors, executive officers and employees of Uroplasty and Vision-Sciences may have direct or indirect interest in the transaction due to securities holdings, vesting of equity awards and rights to severance payments. Additional information regarding the participants in the solicitation of Uroplasty and Vision-Sciences shareholders will be included in the joint proxy statement/prospectus filed with the SEC.
